Abstract
BackgroundThe oral Janus kinase inhibitor tofacitinib (Tofa) was licensed in Switzerland in 2013 for the treatment of moderate to severe rheumatoid arthritis (RA) patients having failed methotrexate. Besides Tofa, rheumatologists...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have